Welcome to our dedicated page for enGene Holdings news (Ticker: ENGN), a resource for investors and traders seeking the latest updates and insights on enGene Holdings stock.
enGene Holdings Inc. (ENGN) is a clinical-stage biotechnology pioneer developing non-viral gene therapies through its proprietary DDX delivery platform. This page serves as the definitive source for verified company news and press releases, providing stakeholders with timely updates on therapeutic advancements and corporate developments.
Investors and researchers will find curated information spanning clinical trial progress, regulatory milestones, and strategic partnerships. Our collection focuses on critical updates including:
- Phase developments for lead candidate EG-70 in bladder cancer treatment
- Innovations in mucosal-targeted gene delivery systems
- Collaborations advancing genetic medicine applications
- Peer-reviewed research publications and conference presentations
Bookmark this page for direct access to primary source materials from enGene, ensuring you stay informed about advancements in localized gene therapy solutions addressing high-need oncological conditions. All content is vetted for accuracy and updated systematically to reflect the company's progress in transforming genetic medicine.
enGene Holdings Inc. (Nasdaq: ENGN) reported its Q3 2024 financial results and provided a business update. The company, focused on developing detalimogene voraplasmid for high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), remains on track to release preliminary LEGEND study data in September 2024. Key financial highlights include:
- Cash and cash equivalents of $257.7 million, providing runway into 2027
- Total operating expenses of $16.8 million for Q3 2024
- Net loss of $14.1 million, or $0.32 per share
The company also announced leadership changes, including Ron Cooper joining as CEO and the promotion of Dr. Raj Pruthi to Chief Medical Officer.
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, announced its participation in three upcoming investor conferences in September 2024. The company's lead program, detalimogene voraplasmid, is currently in a pivotal study for high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis).
The conferences include:
- Morgan Stanley 22nd Annual Healthcare Conference on September 5
- Wells Fargo Healthcare Conference on September 6
- H.C. Wainwright 26th Annual Global Investment Conference on September 11
Presentations will be given by Ron Cooper (CEO), Raj Pruthi (CMO), and Alex Nichols (COO). Live webcasts will be available on the enGene website for 90 days after each event.
enGene Holdings Inc. (Nasdaq: ENGN) has granted an inducement equity award to its new CEO, Ron Cooper. The award consists of a non-qualified stock option to purchase 1,250,000 common shares at an exercise price of $8.81 per share, equal to the closing price on July 22, 2024. The option has a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over three years. This grant, approved by the independent Compensation Committee, is in accordance with NASDAQ Listing Rule 5635(c)(4) and is designed to incentivize Mr. Cooper as he joins the company.
enGene Holdings Inc. (Nasdaq: ENGN) has appointed Ron Cooper as its new Chief Executive Officer and Board member, effective July 22, 2024. Cooper succeeds Jason Hanson, who will remain as a strategic advisor. The company also promoted Dr. Raj Pruthi to Chief Medical Officer.
Cooper brings extensive experience in drug development and commercialization, having previously served as President and CEO of Albireo Pharma. He also spent nearly 30 years at Bristol-Myers Squibb in various leadership roles.
enGene is advancing EG-70, its lead product candidate for BCG-unresponsive high-risk Non-Muscle Invasive Bladder Cancer (NMIBC). The company believes EG-70 has the potential to be the most practical treatment option for high-risk NMIBC, offering a unique combination of efficacy, tolerability, and ease of administration.
enGene (Nasdaq: ENGN) reported its Q2 2024 results, showing significant financial and strategic updates. The company has expanded its LEGEND study of EG-70 into high-risk papillary-only NMIBC and plans to release interim data by September 2024. enGene secured a $200 million private placement in February and has $264.8 million in cash as of April 2024, expected to fund operations into 2027. However, its net loss increased to $15.0 million from $6.5 million YoY due to rising operating expenses. Additionally, the company announced key leadership changes and the deprioritization of the EG-i08 program for cystic fibrosis.
enGene Holdings, a clinical-stage genetic medicines company, announced that their CEO, Jason Hanson, will present a corporate overview at the Jefferies Global Healthcare Conference.
The event will take place in New York City on June 5, 2024, at 12:30 p.m. ET.
enGene's lead program, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
The presentation will be webcast live and archived on the enGene website for 90 days.
enGene Holdings Inc. (Nasdaq: ENGN) announced an oral presentation at the American Urology Association 2024 Annual Meeting regarding its non-viral gene therapy EG-70 for BCG-unresponsive non-muscle invasive bladder cancer. The presentation highlights the rational design of EG-70 to address challenges faced by other treatment options. Promising Phase 1 data show complete response rates of 70% and 60% at three and six months, respectively, with encouraging safety results.
FAQ
What is the current stock price of enGene Holdings (ENGN)?
What is the market cap of enGene Holdings (ENGN)?
